| 发明名称 | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxo1-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid | ||
| 摘要 | The present invention relates to a substantially crystalline and free solid state form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Form I), pharmaceutical compositions thereof, and methods of treatment therewith. | ||
| 申请公布号 | US8846718(B2) | 申请公布日期 | 2014.09.30 |
| 申请号 | US201313933223 | 申请日期 | 2013.07.02 |
| 申请人 | Vertex Pharmaceuticals Incorporated | 发明人 | Keshavarz-Shokri Ali;Zhang Beili;Krawiec Mariusz |
| 分类号 | A61K31/443;C07D405/12 | 主分类号 | A61K31/443 |
| 代理机构 | Finnegan, Henderson, Farabow, Garrett & Dunner, LLP | 代理人 | Finnegan, Henderson, Farabow, Garrett & Dunner, LLP |
| 主权项 | 1. A method of treating cystic fibrosis in a mammal comprising administering to the mammal an effective amount of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid characterized as Form I, wherein the mammal has a defective gene that causes a deletion of phenylalanine at position 508 of the cystic fibrosis transmembrane conductance regulator amino acid sequence. | ||
| 地址 | Boston MA US | ||